​

MoonLake Immunotherapeutics Ownership | Who Owns MoonLake Immunotherapeutics?

OverviewForecastRevenueFinancialsChart

MoonLake Immunotherapeutics Ownership Summary

MoonLake Immunotherapeutics is owned by 98.75% institutional investors, 15.23% insiders. Bvf inc/il is the largest institutional shareholder, holding 34.73% of MLTX shares. T. Rowe Price Health Sciences is the top mutual fund, with 2.08% of its assets in MoonLake Immunotherapeutics shares.

MLTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMoonLake Immunotherapeutics98.75%15.23%-13.97%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bvf inc/il21.75M34.73%$956.40M
Cormorant asset management, lp8.49M13.56%$373.49M
Fmr3.64M5.82%$160.23M
Avoro capital advisors2.77M4.42%$121.80M
Price t rowe associates inc /md/2.56M4.09%$112.63M
Adage capital partners gp1.82M2.91%$80.25M
Holocene advisors, lp1.63M2.60%$71.51M
Goldman sachs group1.25M2.00%$55.04M
Federated hermes1.13M1.80%$49.62M
Westfield capital management co lp1.12M1.78%$49.14M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bvf inc/il21.75M26.81%$956.40M
Cormorant asset management, lp8.49M21.58%$373.49M
Finepoint capital lp388.83K4.85%$17.10M
Ghost tree capital300.00K4.13%$13.19M
5am venture management282.31K2.78%$12.41M
Bioimpact capital343.24K2.35%$15.09M
Altium capital management lp115.00K2.06%$5.06M
Nationale-nederlanden powszechne towarzystwo emerytalne228.80K1.64%$10.06M
Avoro capital advisors2.77M1.62%$121.80M
Highvista strategies42.25K0.68%$1.86M

Top Buyers

HolderShares% AssetsChange
Goldman sachs group1.25M0.01%1.09M
Marshall wace, llp1.10M0.06%587.68K
Price t rowe associates inc /md/2.56M0.01%425.63K
Camber capital management lp355.00K0.43%355.00K
Nuveen asset management521.71K0.01%325.84K

Top Sellers

HolderShares% AssetsChange
T. rowe price investment management---1.10M
Logos global management lp---750.00K
Fmr3.64M0.01%-726.64K
Adage capital partners gp1.82M0.15%-459.91K
Perceptive advisors---339.01K

New Positions

HolderShares% AssetsChangeValue
Camber capital management lp355.00K0.43%355.00K$15.61M
Altium capital management lp115.00K2.06%115.00K$5.06M
Russell investments group33.56K0.00%33.56K$1.48M
Gsa capital partners llp21.72K0.07%21.72K$955.00K
Legal & general group18.59K0.00%18.59K$817.53K

Sold Out

HolderChange
New york state common retirement fund-140.00
Kbc group nv-565.00
Entrypoint capital-862.00
Quarry lp-3.00K
Teacher retirement system of texas-4.00K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2024116-1.69%62,108,6632.42%981.05%7120.34%25-35.90%
Jun 30, 2024118-9.92%60,643,9062.22%961.08%59-6.35%39-7.14%
Mar 31, 2024131-11.49%59,326,406-0.00%940.97%63-30.77%4220.00%
Dec 31, 202314812.12%59,328,2715.33%990.89%9113.75%3529.63%
Sep 30, 202313257.14%56,323,7270.37%1050.64%809.59%27237.50%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
T. Rowe Price Health Sciences1.31M2.08%64.40K
T. Rowe Price New Horizons667.75K1.06%41.93K
US Small-Cap Growth II Equity Comp667.75K1.06%41.68K
Federated Hermes Kaufmann Growth555.00K0.88%-
Federated Hermes Kaufmann R555.00K0.88%-
Harbor Small Cap Growth Instl537.10K0.85%30.73K
Fidelity Select Health Care519.52K0.83%19.52K
Westfield Capital Mgt Co Sm-Cap Gr Eq506.37K0.81%105.85K
Polar Capital Biotech S Inc500.00K0.80%500.00K
Alger Small Cap Focus Composite483.56K0.77%-

Recent Insider Transactions

DateNameRoleActivityValue
Oct 04, 2024BVF PARTNERS L P/IL Sell$6.63M
Oct 04, 2024BVF PARTNERS L P/IL Sell$41.84M
Oct 04, 2024BVF PARTNERS L P/IL Sell$51.53M
Oct 04, 2024Sturge Simon-Sell$9.19M
Feb 29, 2024Santos da Silva Jorge Chief Executive OfficerSell$264.92K

Insider Transactions Trends

DateBuySell
2024 Q2--
2024 Q1-21
2023 Q442
2023 Q228-
2022 Q21-

MLTX Ownership FAQ

Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics shareholders are primarily institutional investors at 98.75%, followed by 15.23% insiders and -13.98% retail investors. The average institutional ownership in MoonLake Immunotherapeutics's industry, Biotech Stocks , is 47.04%, which MoonLake Immunotherapeutics exceeds.

Who owns the most shares of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s largest shareholders are Bvf inc/il (21.75M shares, 34.73%), Cormorant asset management, lp (8.49M shares, 13.56%), and Fmr (3.64M shares, 5.82%). Together, they hold 54.10% of MoonLake Immunotherapeutics’s total shares outstanding.

Does Blackrock own MoonLake Immunotherapeutics?

BlackRock is not among the top 10 institutional shareholders of MoonLake Immunotherapeutics.

Who is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested, with 26.81% of its assets in 21.75M MoonLake Immunotherapeutics shares, valued at 956.4M$.

Who is the top mutual fund holder of MoonLake Immunotherapeutics shares?

T. Rowe Price Health Sciences is the top mutual fund holder of MoonLake Immunotherapeutics shares, with 2.08% of its total shares outstanding invested in 1.31M MoonLake Immunotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools